Menest Alternatives Compared
Menest | Palbociclib | Kisqali |
|
---|
Menest (esterified estrogens) | Palbociclib | Kisqali (ribociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Atrophic Vaginitis, Breast Cancer - Palliative, Atrophic Urethritis, Breast Cancer, Hypoestrogenism, Oophorectomy, Osteoporosis, Postmenopausal Symptoms, Primary Ovarian Failure... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Liposarcoma, Breast Cancer - Male, Breast Cancer. palbociclib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Menest (esterified estrogens) | More about Palbociclib | More about Kisqali (ribociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Menest has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Palbociclib has an average rating of 6.8 out of 10 from a total of 97 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 29% reported a negative effect. |
Kisqali has an average rating of 8.5 out of 10 from a total of 25 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: Menest side effects in more detail. |
See also: palbociclib side effects in more detail. |
See also: Kisqali side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Menest prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Kisqali prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
Ibrance |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
N/A |
29 hours |
54.7 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 228 drugs are known to interact with Menest:
|
A total of 458 drugs are known to interact with palbociclib:
|
A total of 710 drugs are known to interact with Kisqali:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
|
||||||||||||||||||
First Approval Date | ||||||||||||||||||
September 28, 1977 |
N/A |
March 13, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.